Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 04.05.2026 3 Ann Surg Oncol 2 Anticancer Res 4 BMC Cancer 2 Br J Cancer 1 Breast Cancer 1 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 2 Breast J 1 Cancer Cell 1 Cancer Epidemiol Biomarkers Prev 5 Clin Breast Cancer 1 Clin Cancer Res 4 Eur J Surg Oncol 1 Exp Cell Res 1 Histopathology 1 Int J Cancer 2 J Surg Oncol 6 Lancet Oncol 3 N Engl J Med 1 NPJ Breast Cancer 1 Oncogene 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 1 Radiol Imaging Cancer 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. CHIDA K, Wu R, Kawashima K, Grapes A, et al
   ASO Visual Abstract: Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2- Breast Cancer.
   Ann Surg Oncol. 2026 Apr 28. doi: 10.1245/s10434-026-19705.
   PubMed        
   
   
2. MULLER M, Heil J, Pfob A, Cai L, et al
   ASO Visual Abstract: Predictive Value of Routine Imaging for the Diagnosis of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.
   Ann Surg Oncol. 2026 Apr 28. doi: 10.1245/s10434-026-19723.
   PubMed        
   
   
3. CHIDA K, Wu R, Kawashima K, Grapes A, et al
   ASO Author Reflections: Does Ki67 Gene Expression Capture Immune Infiltration and Predict Chemotherapy Response in ER+/HER2- Breast Cancer?
   Ann Surg Oncol. 2026 Apr 27. doi: 10.1245/s10434-026-19720.
   PubMed        
   
   

   
   Anticancer Res

4. AUGUSTINE P, Chavarria J, Burleson M
   Gossypol Inhibits GLI3-dependent SHH Signaling to Selectively Target SPOP-deficient Breast Cancer Cells.
   Anticancer Res. 2026;46:2317-2327.
   PubMed         Abstract available
   
   
5. KUMAZAKI A, Osawa Y, Imanaka K, Ohmoto Y, et al
   Isolation and Biological Evaluation of Breast Cancer Side Population Cells Using DyeCycle Violet.
   Anticancer Res. 2026;46:2417-2427.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. PERERA R, Wijethunga D, Perera M, Abeywickrama C, et al
   Quality of life in breast cancer survivors: insights from a university hospital in Sri Lanka.
   BMC Cancer. 2026 Apr 25. doi: 10.1186/s12885-026-16023.
   PubMed        
   
   
7. ANDREOU M, Chojnowska K, Filipowicz N, Horbacz M, et al
   Beyond tumors: uninvolved breast tissue of breast cancer patients with adverse prognoses is enriched for pathogenic PIK3CA and TP53 post-zygotic variants.
   BMC Cancer. 2026 Apr 30. doi: 10.1186/s12885-026-16086.
   PubMed         Abstract available
   
   
8. ERRIHANI H, Berrada N, El Bachiri M, Jouhadi H, et al
   Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco.
   BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16005.
   PubMed        
   
   
9. KESKIN GSY, Turgut GG, Yildirim G, Tuzun EK, et al
   Prognostic value of cachexia index in HR +/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
   BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16078.
   PubMed        
   
   

   
   Br J Cancer

10. VALACHIS A, Geisler J, Karihtala P, Tuxen MK, et al
    Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?
    Br J Cancer. 2026 Apr 29. doi: 10.1038/s41416-026-03452.
    PubMed         Abstract available
    
    
11. METSER U, Dayes IS, Parpia S, Eisen AF, et al
    Prospective study on (18)F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.
    Br J Cancer. 2026;134:1387-1392.
    PubMed         Abstract available
    
    

    
    Breast Cancer

12. DOMINGUEZ GARCIA A, Mullan BA, Hill K, Breen LJ, et al
    Short- and long-term effectiveness of physical activity interventions for women living with and beyond breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2026 Apr 27. doi: 10.1007/s12282-026-01859.
    PubMed        
    
    

    
    Breast Cancer (Dove Med Press)

13. JIANG X, Wang S, Wei Q, Yang Y, et al
    Novel Insights into the Oncogenic Role and Clinical Significance of ORC6L in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:586715.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

14. LI T, Lian B, Liu Y, Guo L, et al
    Identification and validation of an intratumor heterogeneity-related prognostic signature in triple-negative breast cancer: a study based on integrative machine learning and single-cell sequence.
    Breast Cancer Res. 2026 Apr 25. doi: 10.1186/s13058-026-02291.
    PubMed        
    
    
15. LI Y, Li Z, Dai J
    Tumor-infiltrating lymphocytes in triple-negative breast cancer: molecular mechanisms, spatial regulation, and therapeutic implications.
    Breast Cancer Res. 2026 Apr 26. doi: 10.1186/s13058-026-02285.
    PubMed        
    
    
16. HARA M, Hachiya T, Furukawa T, Nishida Y, et al
    Predictive performance of breast cancer polygenic risk scores from diverse ancestries: a prospective study in Japanese women.
    Breast Cancer Res. 2026 Apr 28. doi: 10.1186/s13058-026-02256.
    PubMed        
    
    
17. SONG PN, DeMellier CT, Lynch SE, Gallegos CA, et al
    CD8 immunoPET imaging to stratify response and guide combination immunotherapy and radiation in triple negative breast cancer.
    Breast Cancer Res. 2026 Apr 25. doi: 10.1186/s13058-026-02286.
    PubMed        
    
    
18. WANG XP, Han Y, Yao M, Gao HW, et al
    AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening.
    Breast Cancer Res. 2026;28:76.
    PubMed         Abstract available
    
    

    
    Breast J

19. OZTEKIN PS, Ozdemir O, Yakistiran S, Altiner S, et al
    Imaging Findings in Patients With Benign Adenomyoepithelioma: A Retrospective Analysis.
    Breast J. 2026;2026:e9666015.
    PubMed         Abstract available
    
    
20. XIAO J, Zhou X, Wang Y, Wu H, et al
    Cancer-Associated Adipocytes in Human Breast Cancer: An Observational Histopathological Study of Dedifferentiation and Stromal Transition.
    Breast J. 2026;2026:e5673713.
    PubMed         Abstract available
    
    

    
    Cancer Cell

21. JASSOWICZ L, Feng F, Warta R, Heinicke F, et al
    Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes.
    Cancer Cell. 2026 Apr 27:S1535-6108(26)00170-4. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

22. ABUBAKAR AK, Jamil H, Tanaka H, Katanoda K, et al
    Trends in Female Breast Cancer Incidence among Japanese, Korean, and U.S. Populations: An Age-Period-Cohort Analysis.
    Cancer Epidemiol Biomarkers Prev. 2026 May 1. doi: 10.1158/1055-9965.EPI-26-0101
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

23. NIEMANN B, Harvey W, Ranson K, Espinosa C, et al
    Thromboelastography Characterizes the Hypercoagulable State in Murine and Human Breast Cancer.
    Clin Breast Cancer. 2026 Apr 1:S1526-8209(26)00050.
    PubMed         Abstract available
    
    
24. KUMAR S, Pathak N, Pezo RC
    Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4/6 Inhibitors: Prognostic and Therapeutic Implications.
    Clin Breast Cancer. 2026;26:91-99.
    PubMed         Abstract available
    
    
25. GILBERT D, Thakur A, Tabernacki T, Loria M, et al
    Breast Cancer in Transgender Patients Following Medical and Surgical Intervention.
    Clin Breast Cancer. 2026;26:100-111.
    PubMed         Abstract available
    
    
26. GASPAR T, Imbassahy D, Duarte BN, Alem CER, et al
    Uptake of Cascade Genetic Testing for Hereditary Breast Cancer in the Public Health System in a Middle-Income Country: A Real-World Study.
    Clin Breast Cancer. 2026;26:83-90.
    PubMed         Abstract available
    
    
27. ZARE M, Mohebbi A, Mohammadi A, Tavangar SM, et al
    Beyond Pathology: MRI-derived Metrics Unlock Preoperative Prognostic Risk Stratification in Breast Cancer.
    Clin Breast Cancer. 2026 Mar 27:S1526-8209(26)00049.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

28. AKAY M, Glendenning J, Tovey H, Tsai YT, et al
    A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.
    Clin Cancer Res. 2026 Apr 28. doi: 10.1158/1078-0432.CCR-26-0041.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

29. WEI T, Li Y, Zhang Z, Xu Y, et al
    Global burden, trends, and attributable risk factors of women's cancers with projection to 2050: Results from the GLOBOCAN 2022 and global burden of disease study 2021.
    Eur J Surg Oncol. 2026;52:111742.
    PubMed         Abstract available
    
    
30. GALASSO E, Delvecchio A, Tedeschi M, Ratti F, et al
    Robotic liver resection for non colorectal metastases: how to deal with it. A multi-center case series.
    Eur J Surg Oncol. 2026;52:111748.
    PubMed         Abstract available
    
    
31. KARHUNEN-ENCKELL U, Salminen A, Tolonen T, Joukainen S, et al
    Factors associated with resection volume and reoperation rates in breast-conserving surgery.
    Eur J Surg Oncol. 2026;52:111735.
    PubMed         Abstract available
    
    
32. DOGAN L, Gulcelik MA, Karanlik H, Akinci M, et al
    Long-term oncological outcomes in early-stage breast cancer patients who underwent upfront oncoplastic breast-conserving surgery: Results from the Turkish oncoplastic breast surgery working group (TOBSWG) database.
    Eur J Surg Oncol. 2026;52:111834.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

33. YE M, Wang Z, Wang Y, Sun Z, et al
    Chemogenetic Screen Identifies EphA2 as a Synthetic Lethal Vulnerability in MYC-Driven Triple-Negative Breast Cancer.
    Exp Cell Res. 2026 Apr 22:115044. doi: 10.1016/j.yexcr.2026.115044.
    PubMed         Abstract available
    
    

    
    Histopathology

34. LIU L, Graff SL, Hacking S, Cheng L, et al
    Genomic and clinicopathological characteristics of low oncotype recurrent score breast cancers with subsequent metastasis.
    Histopathology. 2026;88:1451-1458.
    PubMed         Abstract available
    
    

    
    Int J Cancer

35. HORNER M, Schaffler H, Haberle L, Goossens C, et al
    Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Result
    Int J Cancer. 2026 Apr 29. doi: 10.1002/ijc.70528.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

36. WANG B, Liu S, Huang Z, Wang J, et al
    The Role of Primary Tumor Resection in De Novo Bone-Only Metastatic Breast Cancer: A Propensity Score-Matched Analysis.
    J Surg Oncol. 2026 Apr 29. doi: 10.1002/jso.70277.
    PubMed         Abstract available
    
    
37. PEPIN A, Almeida ND, Fung-Kee-Fung S, Kassick M, et al
    Boost Approaches in Patients Undergoing Postoperative Radiotherapy.
    J Surg Oncol. 2026;133:773-784.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

38. PFOB A, Pham TH, de Boniface J, Gentilini OD, et al
    Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials.
    Lancet Oncol. 2026;27:604-613.
    PubMed         Abstract available
    
    
39. BESHR MS, Fahaid A, Shembesh RH, Valachis A, et al
    CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials.
    Lancet Oncol. 2026;27:592-603.
    PubMed         Abstract available
    
    
40. WANDER SA, Lloyd MR, Keenan JC, Scott EC, et al
    Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
    Lancet Oncol. 2026;27:580-591.
    PubMed         Abstract available
    
    
41. MELLOR D
    Turning breast cancer into art with Cancer Research UK.
    Lancet Oncol. 2026;27:549-550.
    PubMed        
    
    
42. PILEHVARI A, You W, Anderson RT, Kimmick G, et al
    Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer.
    Lancet Oncol. 2026;27:529-531.
    PubMed        
    
    
43. FAN L, Shao ZM
    AKT-targeted triplet therapy in advanced breast cancer.
    Lancet Oncol. 2026;27:528-529.
    PubMed        
    
    

    
    N Engl J Med

44. METZGER O
    Palbociclib for HR-Positive, HER2-Positive Breast Cancer. Reply.
    N Engl J Med. 2026;394:1765-1766.
    PubMed        
    
    
45. LI F, Zhang L
    Palbociclib for HR-Positive, HER2-Positive Breast Cancer.
    N Engl J Med. 2026;394:1764-1765.
    PubMed        
    
    
46. JING S, Song J
    Palbociclib for HR-Positive, HER2-Positive Breast Cancer.
    N Engl J Med. 2026;394:1764.
    PubMed        
    
    

    
    NPJ Breast Cancer

47. O'SHAUGHNESSY J, Bidard FC, Neven P, Casalnuovo ML, et al
    Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.
    NPJ Breast Cancer. 2026 Apr 27. doi: 10.1038/s41523-026-00950.
    PubMed         Abstract available
    
    

    
    Oncogene

48. SPELLECY O, Qadir J, Han R, Zhu K, et al
    Crosstalk between integrin signaling and NAD(+) biosynthetic pathways promotes glycolysis, proliferation, survival, and tumor growth in triple-negative breast cancer.
    Oncogene. 2026 Apr 29. doi: 10.1038/s41388-026-03780.
    PubMed         Abstract available
    
    

    
    PLoS One

49. RUJIMONGKON K, Adchariyasakulchai P, Boonyaratsewee C, Horpratraporn K, et al
    Ivermectin inhibits ER, HER2, and TGF-beta pathways in ER-positive and endocrine-resistant breast cancer cells.
    PLoS One. 2026;21:e0348260.
    PubMed         Abstract available
    
    
50. LAZA-VASQUEZ C, Roman M, Delaloge S, De Montgolfier S, et al
    "Unanswered questions": Acceptability of a personalised breast cancer screening strategy in lower-risk women by healthcare professionals in the context of the MyPeBS study.
    PLoS One. 2026;21:e0347029.
    PubMed         Abstract available
    
    
51. COLWELL S, Chalise P, Gajewski B, Ratnayake I, et al
    Spatial and temporal modeling of breast cancer mortality in Kansas: An R-INLA approach.
    PLoS One. 2026;21:e0347607.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

52. GARRIDO A, Tamayo-Torres E, Abdo S, Durham E, et al
    The antimetastatic effects of calorie restriction are negated by voluntary exercise in an aggressive breast cancer mouse model.
    Proc Natl Acad Sci U S A. 2026;123:e2524488123.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

53. SCHNITZLER T
    Imaging the Breast Cancer Microenvironment: Toward Interpretable MRI Biomarkers for Treatment Response.
    Radiol Artif Intell. 2026;8:e260266.
    PubMed        
    
    

    
    Radiol Imaging Cancer

54. AMIR T, Lee CH, Eskreis-Winkler S, Hogan MP, et al
    Interval Cancers after Negative Screening Contrast-enhanced Mammography.
    Radiol Imaging Cancer. 2026;8:e250559.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

55. ARRIGO A, Brants L, Kramp L, Vanreusel V, et al
    FLASH radiotherapy induces unique immunotranscriptomic profiles compared to conventional dose-rate radiotherapy, despite identical immune infiltration and antitumor efficacy in a murine model of triple-negative breast cancer.
    Radiother Oncol. 2026 Apr 28:111548. doi: 10.1016/j.radonc.2026.111548.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum